Susan Sabo-Wagner, MSN, RN, OCN, of the American Oncology Network, expressed excitement toward networking, innovative discussions, and panels on patient advocacy at Patient-Centered Oncology Care® (PCOC) 2024.
Patient-Centered Oncology Care® (PCOC) 2024 will take place in Nashville, Tennessee, from September 12 to 13. The meeting will showcase experts in the oncology space with discussions surrounding recent innovations that target patient care to increase quality of life.
Susan Sabo-Wagner, MSN, RN, OCN, vice president of clinical innovation at the American Oncology Network, serves as cochair for PCOC this year. In this interview, she explains why she is looking forward to networking and the panels on patient advocacy.
This transcript has been lightly edited for clarity.
Transcript
What are you looking forward to most as cochair of PCOC this year?
The things that I'm most looking forward to is, number one, networking. I think PCOC really brings [together] quite a large group of very interesting people across the oncology spectrum. I love to get together to see everybody that comes to that. I think there's a lot of very interesting speakers this year, from the keynote to all of the different panels.
I was actually just taking a look at the agenda this morning, and I'm very interested in some of the innovation discussions and a lot of the specific discussions on that. Then I saw that there's a couple of prizes, so I think that's a really cool addition this year.
What panels or specific topics are you looking forward to being discussed at PCOC?
I think anything around patient-specific advocacy. There's a couple of different panels dedicated to the different aggregating organizations, and I think that's going to be very interesting to understand. And I think just kind of getting to know what everybody's doing in this space. There's been a lot of changes and reimbursement changes this year, so understanding how everyone is impacted and how they're making changes to face those.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More